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Abstract
Background
Uterine fibroids are common, often symptomatic and a third of women need repeated time
off work. Consequently 25% to 50% of women with fibroids receive surgical treatment,
namely myomectomy or hysterectomy. Hysterectomy is the definitive treatment as fibroids
are hormone dependent and frequently recurrent. Medical treatment aims to control symp-
toms in order to replace or delay surgery. This may improve the outcome of surgery and pre-
vent recurrence.
Purpose
To determine whether any medical treatment can be recommended in the treatment of
women with fibroids about to undergo surgery and in those for whom surgery is not planned
based on currently available evidence.
Study Selection
Two authors independently identified randomised controlled trials (RCT) of all pharmacolog-
ical treatments aimed at the treatment of fibroids from a list of references obtained by formal
search of MEDLINE, EMBASE, Cochrane library, Science Citation Index, and ClinicalTrials.
gov until December 2013.
Data Extraction
Two authors independently extracted data from identified studies.
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Data Synthesis
A Bayesian network meta-analysis was performed following the National Institute for Health
and Care Excellence—Decision Support Unit guidelines. Odds ratios, rate ratios, or mean
differences with 95% credible intervals (CrI) were calculated.
Results and Limitations
A total of 75 RCT met the inclusion criteria, 47 of which were included in the network meta-
analysis. The overall quality of evidence was very low. The network meta-analysis showed
differing results for different outcomes.
Conclusions
There is currently insufficient evidence to recommend any medical treatment in the man-
agement of fibroids. Certain treatments have future promise however further, well designed
RCTs are needed.
Introduction
Uterine fibroids are benign tumours of the uterus known as leiomyomas. Malignant transforma-
tion is rare. The prevalence of uterine fibroids varies between 5% and 65% depending on age,
ethnicity, geographical region and quality of imaging techniques [1–5]. They can occur as single
or multiple focal fibroids or can be diffuse [5, 6]. The mechanism for development of uterine
fibroids is poorly understood. Both genetic factors such as mutations and environmental factors
such as obesity have been implicated in the development of fibroids [7].Additionally they can be
estrogen and progesterone dependent [8]. Symptoms related to fibroids include bleeding irregu-
larities such as heavy, prolonged or irregular periods which may result in iron deficiency, anae-
mia, subfertility and preterm birth [4, 9–11]. Enlargement of the tumor may cause a mass effect
such as pressure on the urinary bladder depending on the anatomical location of the fibroids, or
may experience chronic pelvic pain, and pain during sexual intercourse. The proportion of
women with fibroids who are symptomatic varies with the size and location of the fibroids with
at least 60% of women suffering from one or more symptoms [4, 10, 11]. Classification and sub-
classification by fibroid position and size is important. Such factors have clinical and research
implications. The FIGO PALM-COEIN classification listed eight types of leiomyoma however
there is ongoing debate regarding interpretation [12]. Approximately 25% to 50% require treat-
ment [5]. It is suggested that these symptoms and sequelae may decrease the health-related qual-
ity of life [13, 14], with 30% suffering symptoms severe enough to miss work [14].
Fibroid treatment includes medical and surgical management. In the USA, between 22 and
63% of women who seek medical help for symptoms related to uterine fibroids undergo surgi-
cal management while the remaining women undergo short-term medical treatment with hor-
monal agonists and antagonists [15]. Of the women who undergo surgical treatment, 84–94%
undergo hysterectomy (mostly open or vaginal hysterectomies), 5–9% undergo myomectomy
(removal of fibroids; mostly open), 1–4% undergo endometrial ablation (removal or destruc-
tion of the endometrium), and 1–3% undergo uterine artery embolization (obstruction of
blood flow to uterine artery). The direct treatment costs (including the costs of medical treat-
ments involved in surgery) in US have been estimated to be between US $6,000 and $12,000 for
hysterectomy, between $7,000 and $15,000 for myomectomy, between US $7,000 and $13,000
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for uterine artery embolization, US$5,000 for endometrial ablation, and between US $6,000
and $9,000 for non-surgical treatment [15, 16]. Thus, uterine fibroids cause a large socioeco-
nomic burden.
Although hysterectomy is generally considered a safe operation, complications occur in a
significant proportion of patients [15]. These include intra-operative bleeding (about 5% of
people undergoing hysterectomy), post-operative fever (about 40% of people undergoing hys-
terectomy), post-operative surgical site infection (20%), deep vein thrombosis (symptomatic in
<1%), vaginal cuff dehiscence (<1%), lower urinary tract injury (5%), gastrointestinal injury
(<1%), and femoral or sciatic neuropathy (1% to 2%) [17]. There are alternative medical treat-
ments. A variety of treatments have been used for uterine fibroids which take advantage of
their hormonal dependence. These include gonadotropin releasing hormone (GnRH) ana-
logues such as buserelin and, goserelin, selective estrogen receptor modulators (SERM) such as
raloxifene, selective progesterone receptor modulators (SPRM) such as ulipristal, and proges-
terone antagonists such as mifepristone [18–21]. These drugs shrink the size of the fibroid and
uterine volume [22] and hence have the potential to provide relief from symptoms in patients
who undergo medical treatment. These drugs also provide symptomatic relief in patients wait-
ing for surgery and enable vaginal or laparoscopic surgery, allowing a shorter hospital stay and
quicker return to normal activities compared with open surgery [23]. Many of these drugs have
a significant adverse event profile which limit the duration of administration. For example,
GnRH analogues cause hypoestrogenism which leads to hot flushes and bone loss, limiting the
treatment to a maximum of 3 to 6 months. These drugs are also associated with significant
costs. While several meta-analyses have been performed comparing different medical treat-
ments used in the management of fibroids [18–20], there has been no multiple treatment com-
parison meta-analysis or network meta-analysis. Such an analysis allows comparison of
multiple treatments simultaneously and a Bayesian analysis allows ranking of treatments based
on probability of being the best treatment [24]. The aim of this research is to determine
whether any medical treatment is useful in the treatment of women with fibroids about to
undergo surgery and in those for whom surgery is not planned.
Methods
The systematic review was conducted following the PRISMA (Transparent Reporting of Sys-
tematic Reviews and Meta-analyses) reporting standards, those of the Cochrane collaboration,
and the National Institute for Health Research and Clinical Excellence Decision Support Unit
(NICE DSU) guidelines [25–27]. The detailed process is described in S1 Appendix. In short,
randomised controlled trials which addressed one of the following comparisons were included.
1. Medical versus surgical treatments for fibroids.
2. Different medical treatments for fibroids (studies that compared different doses of the same
drug were excluded unless the different drugs were compared with another drug or inactive
control).
3. Different medical treatments prior to surgical treatment of fibroids (as before, studies that
compared different doses of the same drug were excluded unless the different drugs were
compared with another drug or inactive control).
The outcomes assessed for the first comparison included proportion requiring hysterec-
tomy, quality of life, successful pregnancies, and costs.
The outcomes assessed for the second and third comparisons included proportion requiring
subsequent surgery, treatment related adverse events, quality of life, blood transfusion
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requirements (proportion transfused and amount transfused), haemoglobin levels, successful
pregnancies, length of hospital stay, and costs. In the comparison between different medical treat-
ments prior to surgical treatment, the outcomes assessed included mortality, proportion under-
going laparoscopic or vaginal hysterectomy and laparoscopic or hysteroscopic myomectomy as
applicable, treatment related adverse events, quality of life, blood transfusion requirements, hae-
moglobin levels, successful pregnancies (in only those in reproductive age group undergoing
myomectomy), and resource measures such as length of hospital stay, operating time, and overall
costs. The Cochrane library, MEDLINE, EMBASE, Science Citation Index Expanded, and Clini-
calTrials.gov were searched until December 2013. The search strategies are available in S1
Appendix. The references of the included trials were searched to identify further trials. Two
authors (KG and JV), independently identified the trials for inclusion and extracted data related
to the outcomes mentioned above and assessed the risk of bias (according to Cochrane tools) in
the trials. All differences in opinion were resolved by discussion until consensus was reached.
The software Winbugs 1.4 was used to perform the network meta-analysis using a Bayesian
framework. The models used for analysis were based on those available from NICE DSU. Bino-
mial likelihood was used for binary outcomes such as proportion of people with successful
pregnancies, poisson likelihood for count outcomes such as number of adverse events and for
binary outcomes with too many zeros that did not allow the analysis by binomial likelihood,
and normal likelihood for continuous outcomes to calculate the odds ratio, rate ratio, and
mean difference (MD) with 95% credible intervals (CrI) respectively. We used normal distribu-
tion with large variance (10,000) (non-informative priors) for treatment effects to ensure that
the choice of prior does not influence the posterior probabilities [27]. Three different starting
points (initial values) (three chains) were used and a burn-in of 30,000 iterations to ensure that
the final results were not dependent on the starting point. A further 30,000 iterations were run
to obtain the effect estimates. The probability of being the best treatment, the probability of
being one of the best two treatments, best three treatments and so on [24] was calculated for
each outcome to generate a cumulative ranking probability.
Exploration of publication bias and other reporting bias by funnel plot asymmetry and
Egger's regression method of exploration of publication bias [28] was planned but not per-
formed because there were less than 10 trials for comparing the same intervention and control.
Summary of findings tables providing the number of studies and participants included in
the network meta-analysis, quality of the evidence based on GRADE methodology [29], the rel-
ative effect (odds ratio or rate ratio) or the mean difference for each pairwise comparison, and
illustrative absolute effect for odds ratio or rate ratio were created for each outcome based on
the mean control group proportion or rate (for odds ratio and rate ratio respectively) and con-
trol group mean for mean difference and are available in S3 Appendix.
Results
A total of 4237 references were identified by searching the electronic databases and the other
sources. A total of 146 full texts were sought and 86 references [30–115] of 75 randomised con-
trolled trials were included for this systematic review. Forty seven trials contributed to the net-
work meta-analysis. The reference flow is shown in Fig 1. The characteristics of included
studies are given in tables 1 and 11 in S3 Appendix for medical treatment and surgical treat-
ment respectively.
Most trials included premenopausal women with symptomatic fibroids. The size of the
fibroids varied between the studies. The details of size of the fibroids, menstrual status of the
women, and the type of surgery, if any, that the women underwent are available in S2 Appen-
dix and S3 Appendix.
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Effect estimates
Results are summarised in Table 1. The detailed results are available in S2 Appendix and S3
Appendix. There was no evidence of inconsistency for any of the analyses.
Medical versus surgical treatment. Two trials compared medical versus surgical treat-
ment [64] [77]. In one trial, the control group received surgery immediately [64] and in
another trial, the control group underwent medical treatment and endometrial resection rou-
tinely [77]. The randomised participants were followed up for 3 years in the first trial [64]
which included 72 premenopausal women with> 10 cm fibroids randomised to medical and
surgical treatment and for 1 year in the second trial which included 25 premenopausal women
Fig 1. Reference flow diagram.
doi:10.1371/journal.pone.0149631.g001
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with symptomatic fibroids with uterine size between 12 weeks and 16 weeks gestation rando-
mised to medical and surgical treatment [77]. Both trials were at unclear or high risk of bias in
most domains. The risk ratio of undergoing hysterectomy at 3 years in the first trial [64] was
statistically significantly lower in the medical treatment group than direct surgery group (RR
0.41; 95% CrI 0.29 to 0.57; P< 0.00001). The proportion of people who underwent hysterec-
tomy at 12 months was not statistically significant between the medical treatment and medical
Table 1. Summary of results.
Outcome Statistically signiﬁcant comparisons Effect estimate of statistically signiﬁcant comparisons
(95% CrI) (non-signiﬁcant comparisons are not shown)
Medical versus surgical treatment
Proportion undergoing
hysterectomy
Medical treatment versus routine hysterectomy RR 0.41; 95% CrI 0.29 to 0.57
Medical treatment in women not scheduled to undergo surgerya
Proportion undergoing surgery Tibolone/leuprolide versus placebo OR 0.08; 95% CrI 0.01 to 0.47
Proportion with adverse
events
No statistically signiﬁcant differences between any
of the pairwise comparisons
Not applicable
Number of adverse events Leuprolide versus placebo OR 5.57; 95% CrI 3.63 to 8.57
Mifepristone versus placebo OR 1.51; 95% CrI 1.09 to 2.08
Medroxyprogesterone/leuprolide versus placebo OR 3.33; 95% CrI 1.1 to 10.03
Raloxiphene/leuprolide versus placebo OR 3.78; 95% CrI 1.07 to 13.41
Leuprolide versus asoprisnil OR 3.87; 95% CrI 2.16 to 6.92
Mifepristone versus leuprolide OR 0.27; 95% CrI 0.16 to 0.46
Haemoglobin Leuprolide versus placebo MD 0.77; 95% CrI 0.37 to 1.17
Mifepristone versus placebo MD 1.88; 95% CrI 1.06 to 2.69
Raloxiphene/leuprolide versus placebo MD 0.97; 95% CrI 0.23 to 1.70
Ulipristal versus placebo MD 0.96; 95% CrI 0.61 to 1.31
Mifepristone versus Leuprolide MD 1.11; 95% CrI 0.2 to 2.02
Medical treatment prior to planned surgeryb
Proportion with adverse
events
Goserelin versus placebo OR 6.35; 95% CrI 3.33 to 12.10
Number with adverse events Goserelin versus no active treatment OR 1.66; 95% CrI 1.33 to 2.06
Leuprolide versus no active treatment OR 1.38; 95% CrI 1.17 to 1.62
Proportion undergoing
abdominal hysterectomy
Leuprolide versus no active treatment OR 0.55; 95% CrI 0.4 to 0.75
Proportion undergoing blood
transfusion
Goserelin versus no active treatment OR 0.40; 95% CrI 0.22 to 0.75
Leuprolide versus no active treatment OR 0.38; 95% CrI 0.2 to 0.71
Hospital stay No statistically signiﬁcant differences between any
of the pairwise comparisons
Not applicable
Operating time Leuprolide versus no active treatment MD -8.56; 95% CrI -15.28 to -1.84
Haemoglobin Leuprolide versus no active treatment MD 1.28; 95% CrI 0.93 to 1.63
Mifepristone versus no active treatment MD 1.10; 95% CrI 0.04 to 2.15
Tibolone/leuprolide versus no active treatment MD 1.16; 95% CrI 0.65 to 1.66
OR = odds ratio. RaR = rate ratio. MD = mean difference. CrI = credible interval
a Proportion of people who underwent blood transfusion or amount of blood transfused, proportion of people with successful pregnancies, length of
hospital stays, and costs were not reported in any of the trials. Meta-analysis of quality of life outcomes was not performed because of incompatibility of
reporting methods. A narrative summary can be found in S2 Appendix.
b Quality of life, amount of blood transfused, cost of treatment, proportion with a successful pregnancy and proportion undergoing abdominal myomectomy
did not provide data for meta-analysis
doi:10.1371/journal.pone.0149631.t001
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treatment followed by endometrial resection groups in the second trial (RR 5.54; 95% CrI 0.78
to 39.57; P = 0.09) [77]. However, neither of these trials reported any other outcome and so we
were unable to determine whether there was any significant difference in mortality, number of
successful pregnancies or the overall quality of life between medical and surgical treatment.
These results are shown in Fig 2.
Medical treatment in women not scheduled to undergo surgery. Outcomes investigated
were: proportion requiring surgery; treatment related adverse events; quality of life; blood
transfusion requirements (proportion and amount transfused); haemoglobin levels; successful
pregnancies; length of hospital stay and costs.)
The proportion of women requiring surgery in the short-term was statistically significantly
lower in the tibolone/leuprolide group compared to no treatment (OR 0.08; 95% CrI 0.01 to
0.47). There were no statistically significant differences in the proportion of people with
adverse events between any of the treatments and the placebo. Leuprolide (OR 5.57; 95% CrI
3.63 to 8.57), mifepristone (OR 1.51; 95% CrI 1.09 to 2.08), medroxyprogesterone/leuprolide
(OR 3.33; 95% CrI 1.1 to 10.03) and raloxiphene/leuprolide (OR 3.78; 95% CrI 1.07 to 13.41)
had statistically significant more adverse events than the placebo group. Leuprolide had statisti-
cally significantly more adverse events than asoprisnil (OR 3.87; 95% CrI 2.16 to 6.92) and
mifepristone had significantly fewer adverse events than leuprolide (OR 0.27; 95% CrI 0.16 to
0.46). All six studies reporting quality of life as an outcome found an increased quality of life
scores with medical treatments, because of incompatibility of different reporting methos used
meta-analysis is not appropriate. A more detailed narrative summary can be found in S2 App.
Four treatments were found to statistically significantly increase haemoglobin levels compared
to a group receiving placebo. These included: leuprolide (MD 0.77; 95% CrI 0.37 to 1.17),
mifepristone (MD 1.88; 95% CrI 1.06 to 2.69), raloxiphene/leuprolide (MD 0.97; 95% CrI 0.23
to 1.7) and ulipristal (MD 0.96; 95% CrI 0.61 to 1.31). Mifepristone was found to cause signifi-
cantly higher haemoglobin levels than leuprolide (MD 1.11; 95% CrI 0.20 to 2.02). These
results are summarised in Fig 3. More detailed results are described in S2–S17 Figs, including
forest plots and cumulative probability rankings.
The effect estimates of each pairwise comparison are available in tables 3–10 in S3 Appen-
dix. The proportion of people with successful pregnancies, proportion of people who under-
went blood transfusion or amount of blood transfused, length of hospital days, and costs were
not reported in any of the trials.
Medical treatment in women prior to planned surgery. Outcomes investigated were:
proportion undergoing abdominal myomectomy; proportion undergoing abdominal hysterec-
tomy; treatment related adverse events; quality of life; blood transfusion requirements (propor-
tion and amount transfused); haemoglobin levels; successful pregnancies; length of hospital
stay; operating time and costs
Fig 2. Medical treatment versus surgical treatments for uterine fibroids—proportion undergoing abdominal hysterectomy—forest plot.
doi:10.1371/journal.pone.0149631.g002
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The proportion of women with adverse events was statistically significantly higher in the
goserelin group compared to those receiving placebo (OR 6.35; 95% CrI 3.33 to 12.10). Gosere-
lin also caused a statistically significant increase in the number of women with adverse events
compared to the group with no active treatment (OR 1.66; 95% CrI 1.33 to 2.06), as did leupro-
lide (OR 1.38; 95% CrI 1.17 to 1.62). Leuprolide did significantly reduce the proportion of
women undergoing abdominal hysterectomy in the short-term compared to women receiving
no active treatment (OR 0.55; 95% CrI 0.40 to 0.75). Both goserelin (OR 0.40; 95% CrI 0.22 to
0.75) and leuprolide (OR 0.38; 95% CrI 0.20 to 0.71) significantly reduced the proportion of
women undergoing blood transfusion. There were no statistically significant differences in hos-
pital stay between any of the treatments and no active treatment. Leuprolide reduced the oper-
ating time compared to the group receiving no active treatment (MD -8.56; 95% CrI -15.28 to
-1.84). Three treatments were found to statistically increase haemoglobin levels compared to
the group receiving no active treatment. These were: leuprolide (MD 1.28; 95% CrI 0.93 to
1.63), mifepristone (MD 1.10; 95% CrI 0.04 to 2.15) and tibolone/leuprolide (MD 1.16; 95%
CrI 0.65 to 1.66). These results are summarised in Fig 4. More detailed results are described in
S18–S45 Figs, including forest plots and cumulative probability rankings.
The effect estimates of each pairwise comparison are available in tables 13–26 in S3 Appen-
dix. Quality of life, amount of blood transfused, cost of treatment, proportion with a successful
pregnancy and proportion undergoing abdominal myomectomy did not have available data
for meta-analysis.
Discussion
This is the first network meta-analysis assessing the effect of different pharmacological inter-
ventions in the treatment of uterine fibroids.
Fig 3. Different medical treatments in those not scheduled to undergo surgery—rankogram.
doi:10.1371/journal.pone.0149631.g003
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Medical versus surgical treatment
Only two trials compared medical with surgical treatment. Network meta-analysis could not be
performed because of differences in the treatments in the two trials. The trials were at unclear
or high risk of bias for most domains and the overall quality of evidence was poor. The only
outcome of interest reported was the proportion that underwent hysterectomy. The two trials
reported different results and so there is currently no evidence to recommend medical treat-
ment as a substitute for surgical treatment.
Medical treatment in women not scheduled to undergo surgery
The network meta-analyses showed different results for different outcomes. In the ranking of
treatments for different outcomes, more than 80% probability of one treatment being the best
treatment was noted only in the proportion undergoing surgery in which Tibolone/leuprolide
combination was the best treatment, the number of adverse events for which placebo was the
best treatment, and haemoglobin for which mifepristone was the best treatment. The number
of adverse events included disease-related and treatment-related adverse events. The severity of
the adverse events was not reported but most of the adverse events reported appeared to be
mild. In addition, there is currently no evidence to suggest that patients consider one type of
adverse event to be worse than another type. Until the relative importance and the variability
in the relative importance that patients assign to these adverse events is obtained in relation to
the benefits seen in avoiding or postponing surgery, one cannot advocate medical treatment
for the control of symptoms. This may be captured in quality of life instruments. In addition,
the treatment can be given only for short periods of time because of the long-term risks, such
as increased rate of bone loss for GnRH analogues, and it is not clear whether medical
Fig 4. Different presurgical medical treatments—rankogram.
doi:10.1371/journal.pone.0149631.g004
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treatment only delays the inevitable at significant costs and adverse events without any major
advantages. Approximately, 45% of patients who received no active treatment had surgery dur-
ing the follow-up period. A minimum sample size of 932 participants will be required to detect
a 20% reduction in the proportion of patients who require surgery with an alpha error of 0.05
and power of 0.8. The final haemoglobin level is higher for a number of interventions com-
pared to no active treatment but the clinical significance of this difference in haemoglobin is
not known since the trials did not report the blood transfusion requirements. Iron deficiency
itself may be relevant for the treatment of fibroids with associated heavy menstrual bleeding
and post-surgically where it may be slow to correct. Short-term quality of life appears to be
improved for a number of treatments compared to placebo despite the increase in adverse
events. However, long-term follow-up is necessary to determine whether this improvement in
short-term quality of life and reduction in the proportion of people who undergo hysterectomy
persists in the long run. The same reporting methodology must be used in future trials to allow
for meta-analysis of results. Clinically long term assessment is crucial because fibroids are a
long term condition. Short-term trials are of limited value to a gynaecologist deciding treat-
ment for a given patient. A well designed randomised controlled trial with cost-effectiveness
analysis is necessary before medical treatment can be routinely recommended for women with
fibroids who are not scheduled to undergo hysterectomy.
Medical treatment in women prior to planned surgery
The network meta-analyses again showed different results for different outcomes. In the rank-
ing of treatments for different outcomes, more than 80% probability of one treatment being the
best treatment was noted only in the length of hospital stay in which leuprolide was the best
treatment. The trials were at high risk of bias and overall quality of evidence was low. A num-
ber of treatments had more adverse events than inactive treatment. As mentioned earlier, until
the relative importance that patients ascribe to these adverse events is determined, one cannot
advocate medical treatment for the control of symptoms during the waiting time. Although
leuoprolide appears to show benefit in a number of outcomes such as reduction in the propor-
tion of women requiring abdominal hysterectomy, blood transfusion requirement, and length
of hospital stay, the trials were at high risk of bias and the overall quality of evidence was low.
So, no medical treatment can be recommended currently during the waiting time for surgery.
Approximately, 75% of patients who received no active treatment had abdominal hysterec-
tomy. A minimum sample size of 304 participants will be required to detect a 20% reduction in
the proportion of patients who require hysterectomy with an alpha error of 0.05 and power of
0.8. Again, a well-designed randomised controlled trial with cost-effectiveness analysis is neces-
sary before medical treatment can be routinely recommended for women waiting for surgery
for fibroids.
The major strengths of this review were that we followed the PRISMA guidance for report-
ing and included all randomized controlled trials on the topic without any restriction on the
language of publication. We also selected studies and extracted data independently, which
decreases the errors. We chose non-informative priors and used three different chains of initial
values which decreases the risk of error due to the choice or prior and initial values. The major
weaknesses of the review are the risk of bias in the included trials and the sparse data for many
of the outcomes despite the number of trials included in this review.
This is the first network meta-analysis on this topic. Some previous head-to-head compari-
sons found insufficient evidence to support medical treatment for fibroids [18] [20]while one
review advocated the use of pre-operative GnRH analogues [22]. The differences in the conclu-
sion between our review and the review that advocated the use of medical treatment may be
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because of new trials conducted in this field in the last 15 years and the use of clinical outcomes
rather than surrogate outcomes such as decrease in fibroid size.
There is currently no evidence to support the routine use of medical treatment in women
with uterine fibroids. Several treatments appear promising but the efficacy of these drugs
should be assessed in low risk of bias trials powered to measure differences in clinical out-
comes. Ideally these would be both large scale and long term. Ultimately medical treatment
may involve continued treatment over a period of time to prevent surgery.
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